Added to YB: 2024-03-22
Pitch date: 2024-01-23
NTRA [bullish]
Natera, Inc.
+246.19%
current return
Author Info
No bio for this author
Company Info
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Market Cap
$28.2B
Pitch Price
$67.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-91.38
P/E
-89.19
EV/Sales
12.92
Sector
Biotechnology
Category
growth
Next Century Growth Investors SMID Cap Growth Strategy New Portfolio holding: Natera, Inc.
NTRA: Leader in cell-free DNA tests for oncology, women's & organ health. Signatera leads in fast-growing MRD testing. Panorama (NIPT) & Prospera also key. Yrs of investment now driving strong revs & nearing cash flow+. Personalized genetic testing moving to standard of care.
Read full article (1 min)